• Moderna shares tumble 12% in pre-market trading following reports of FDA vaccine chief Peter Marks' forced resignation.
  • The departure raises concerns about vaccine regulation under new HHS leadership and comes amid Moderna's post-pandemic revenue decline.
  • Analysts warn the leadership change could delay new vaccine approvals and undermine public confidence in immunization programs.

Regulatory Shakeup Rattles Biotech Sector

Moderna Inc. (MRNA) shares plummeted 12% in pre-market trading Thursday after Bloomberg reported Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, was forced to resign under pressure from HHS Secretary Robert F. Kennedy Jr. The sudden departure of the agency's top vaccine regulator sent shockwaves through the biotech sector, particularly impacting mRNA vaccine developers like Moderna.

According to three people familiar with the matter, Marks submitted his resignation Wednesday following weeks of tension with Kennedy over vaccine policy. In his resignation letter viewed by Bloomberg, Marks cited concerns about the new administration's stance on vaccines and referenced the ongoing measles outbreak in Texas as evidence of the need for strong regulatory oversight.

Moderna's Challenges Compound

The regulatory uncertainty comes at a difficult time for Moderna, which reported Q4 2024 revenue of $966 million - a 65% year-over-year decline as COVID-19 vaccine demand wanes. The company recently guided for 2025 revenue between $1.5-$2.5 billion, well below pandemic-era peaks, while pursuing cost-cutting measures and pipeline development.

"This creates another headwind for Moderna just as they're trying to transition to a more diversified product portfolio," said a biotech analyst who asked not to be named discussing market-sensitive information. "Marks was instrumental in Operation Warp Speed and understood the science behind mRNA platforms."

Industry Implications

Pharmaceutical executives expressed private concerns that Marks' departure could delay approvals for Moderna's pipeline candidates, including combination flu/COVID vaccines and new RSV immunizations. The FDA veteran had reportedly threatened to resign once before in 2020 when political pressure threatened to compromise vaccine approval standards.

HHS didn't immediately respond to requests for comment. Moderna declined to specifically address the Marks situation but reiterated confidence in its regulatory submissions. The company expects up to 10 product approvals through 2027.

Correction: An earlier version misstated Moderna's 2024 full-year revenue. The correct figure is $3.2 billion.